Oral naratriptan approved for migraine attacks.
D017277:Drug Approval; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014363:Tryptamines; D014481:United States; D014486:United States Food and Drug Administration
D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C106783:naratriptan